Clinical impact of aripiprazole in patients suffering from schizophrenia;Aripiprazole: À propos de cas cliniques chez des patients souffrant de schizophrénie ou d'un trouble schizo-affectif

Encephale

Volumn 33, Issue 3, 2007, Pages 332-338

  Levoyer, D ^b   Drapier, D ^b   Fadier Salice G ^b   Millet, B ^a  

^a RENNES UNIVERSITY HOSPITAL   (France)

^b NONE

Author keywords

Antipsychotics; Aripiprazole; Clinical impact; Schizophrenia; Strategies of prescription

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; DOPAMINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; OLANZAPINE; PARTIAL AGONIST; RISPERIDONE; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; VALPROMIDE;

ADULT; ARTICLE; CLASSIFICATION; CLINICAL ARTICLE; COGNITION; COGNITIVE DEFECT; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; MALE; MENTAL PATIENT; POSITIVE AND NEGATIVE SYNDROME SCALE; RATING SCALE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TREATMENT DURATION; TREATMENT OUTCOME; WORKING MEMORY;

EID: 34547663314     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0013-7006(07)92047-3     Document Type: Article

References (6)

1. BOURIN M. Aripiprazole, a view point. CNS drugs 2004 ; 18 : 377-8.
2. BOURIN M. Mécanisme d'action comparé des différents antipsychotiques. Act Med Int 2004 ; 8 : 201-4.
3. CARPENTER WT, HEINRICHS DW, WAGMAN AM. Deficit and non-deficit forms of schizophrenia : the concept. Am J Psychiatry 1988 ; 145 : 578-83.
4. LOZE JY, KOSTIC D, McQUADE R et al. The effects of aripiprazole on the cognitive symptoms of schizophrenia. J Eur Coll Neuropsychopharmacol 2004 ; 14 (Suppl 3) : S287.
5. NABER D, LAMBERT M. Aripiprazole : a new atypical antipsychotic with a different pharmacological mechanism. Prog Neuropsychopharmacol Biol Psychiatry 2004 ; 28 : 1213-9.
6. PETIT M, THIBAUT F, BELLIR B. Formes négatives et positives de la schizophrénie. In : Olié JP, Daléry J, Azorin JM, eds. Médicaments antipsychotiques : évolution ou révolution ? Paris : ETICOM-Acanthe, 2001 : 371-95.